DiaSorin SpA - Company Profile
Powered by 
All the sales intelligence you need on DiaSorin SpA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how DiaSorin SpA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with DiaSorin SpA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
DiaSorin SpA (DiaSorin) is a medical diagnostics company that is engaged in the development, manufacturing, and marketing of in vitro diagnostics reagent kits and systems. The company specializes in the development, production, and marketing of reagent kits used by diagnostic laboratories worldwide. DiaSorin's major products include a wide range of specialty tests for diagnostics and various solutions for the life science sector. The company's Liaison and Verigene systems, along with its xMAP technology, are some of its notable brands. The company’s immunodiagnostic and molecular diagnostics products find application in the diagnosis of infectious diseases, bone and mineral disorders, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmune disorders, and neurological and cardiac diseases, among others. DiaSorin markets its products through direct sales forces and distributors. It has operations in North America, South America, South Africa, Europe, the Middle East, Africa, and Asia. DiaSorin is headquartered in Saluggia, Piedmont, Italy.
Headquarters
Italy
Address
Via Crescentino Snc, Saluggia, Piemonte, 13040
Website
int.diasorin.com
Telephone
39 016 1487526
No of Employees
3,249
Industry
Medical Equipment
Ticker Symbol & Exchange
DIA (BIT)
Revenue (2024)
$1.3B
0.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-17.3%
(2024 vs 2023)
Market Cap*
$4.4B
Net Profit Margin (2024)
XYZ
-18.0%
(2024 vs 2023)
* As of and is in US$
DiaSorin SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Instruments: | LIAISON |
| Sample to Answer Systems | EVOlyzer |
| xMAP Multiplexing | BioTek |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In June, the company received 510(k) clearance from the US FDA, for LIAISON PLEX Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX. |
| 2025 | Regulatory Approval | In April, the company received 510(k) clearance from the US FDA for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX. |
| 2025 | New Products/Services | In March, the company introduced the Simplexa C. auris direct assay on the LIAISON MDX instrument in all countries with the CE Mark. |
Competitor Comparison
| Key Parameters | DiaSorin SpA | Thermo Fisher Scientific Inc | Siemens Healthineers AG | Danaher Corp | Becton Dickinson and Co |
|---|---|---|---|---|---|
| Headquarters | Italy | United States of America | Germany | United States of America | United States of America |
| City | Saluggia | Waltham | Forchheim | Washington | Franklin Lakes |
| State/Province | Piemonte | Massachusetts | Bayern | WashingtonD.C. | New Jersey |
| No. of Employees | 3,249 | 125,000 | 72,000 | 58,000 | 72,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michele Denegri | Chairman | Executive Board | 2022 | 57 |
| Carlo Rosa | General Manager; Director; Chief Executive Officer | Executive Board | 2022 | 60 |
| Chen Menachem Even, PhD | Director; Chief Commercial Officer | Executive Board | 2022 | 63 |
| Alberto Donati | Chief Financial Officer | Senior Management | 2026 | - |
| Fabrizio Bonelli | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer